In a statement here, company CEO Venkat Jasti said this was Suven's first product patent granted in the US. The granted claims of the patent included the class of selective Serotonin receptor affinity compounds discovered by Suven and were being developed as therapeutic agents. The company had filed 29 patent applications through the Product Cooperation Treaty (PCT), out of which five were granted in various countries.
Several other patent applications from Suven Discovery Research were in the pipeline, that had completed administrative and technical diligence from patent offices of major countries and would be granted shortly.
''We are very pleased by the issuance of this patent by US Patent Office for our drugs, being developed for CNS disorders, which targets a 18 billion US Dollar market,'' Mr Jasti said.